Cargando…
Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections
The fetal/neonatal period represents both a unique window of opportunity for interventions as well as vulnerability to a number of viral infections. While Herpesviruses such as herpes simplex virus (HSV) are highly prevalent and typically of little consequence among healthy adults, they are among th...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398215/ https://www.ncbi.nlm.nih.gov/pubmed/36016956 http://dx.doi.org/10.3389/fimmu.2022.959603 |
_version_ | 1784772285751623680 |
---|---|
author | Backes, Iara M. Leib, David A. Ackerman, Margaret E. |
author_facet | Backes, Iara M. Leib, David A. Ackerman, Margaret E. |
author_sort | Backes, Iara M. |
collection | PubMed |
description | The fetal/neonatal period represents both a unique window of opportunity for interventions as well as vulnerability to a number of viral infections. While Herpesviruses such as herpes simplex virus (HSV) are highly prevalent and typically of little consequence among healthy adults, they are among the most consequential infections of early life. Despite treatment with antiviral drugs, neonatal HSV (nHSV) infections can still result in significant mortality and lifelong neurological morbidity. Fortunately, newborns in our pathogen-rich world inherit some of the protection provided by the maternal immune system in the form of transferred antibodies. Maternal seropositivity, resulting in placental transfer of antibodies capable of neutralizing virus and eliciting the diverse effector functions of the innate immune system are associated with dramatically decreased risk of nHSV. Given this clear epidemiological evidence of reduced risk of infection and its sequelae, we present what is known about the ability of monoclonal antibody therapies to treat or prevent HSV infection and explore how effective antibody-based interventions in conjunction with antiviral therapy might reduce early life mortality and long-term morbidity. |
format | Online Article Text |
id | pubmed-9398215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93982152022-08-24 Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections Backes, Iara M. Leib, David A. Ackerman, Margaret E. Front Immunol Immunology The fetal/neonatal period represents both a unique window of opportunity for interventions as well as vulnerability to a number of viral infections. While Herpesviruses such as herpes simplex virus (HSV) are highly prevalent and typically of little consequence among healthy adults, they are among the most consequential infections of early life. Despite treatment with antiviral drugs, neonatal HSV (nHSV) infections can still result in significant mortality and lifelong neurological morbidity. Fortunately, newborns in our pathogen-rich world inherit some of the protection provided by the maternal immune system in the form of transferred antibodies. Maternal seropositivity, resulting in placental transfer of antibodies capable of neutralizing virus and eliciting the diverse effector functions of the innate immune system are associated with dramatically decreased risk of nHSV. Given this clear epidemiological evidence of reduced risk of infection and its sequelae, we present what is known about the ability of monoclonal antibody therapies to treat or prevent HSV infection and explore how effective antibody-based interventions in conjunction with antiviral therapy might reduce early life mortality and long-term morbidity. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9398215/ /pubmed/36016956 http://dx.doi.org/10.3389/fimmu.2022.959603 Text en Copyright © 2022 Backes, Leib and Ackerman https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Backes, Iara M. Leib, David A. Ackerman, Margaret E. Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title | Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title_full | Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title_fullStr | Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title_full_unstemmed | Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title_short | Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections |
title_sort | monoclonal antibody therapy of herpes simplex virus: an opportunity to decrease congenital and perinatal infections |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398215/ https://www.ncbi.nlm.nih.gov/pubmed/36016956 http://dx.doi.org/10.3389/fimmu.2022.959603 |
work_keys_str_mv | AT backesiaram monoclonalantibodytherapyofherpessimplexvirusanopportunitytodecreasecongenitalandperinatalinfections AT leibdavida monoclonalantibodytherapyofherpessimplexvirusanopportunitytodecreasecongenitalandperinatalinfections AT ackermanmargarete monoclonalantibodytherapyofherpessimplexvirusanopportunitytodecreasecongenitalandperinatalinfections |